Pro 2013-021 (Jianfeng Group Corporate Bond Listing Announcement)-6
Release time:
2020-08-05
第九节 发行人近三年是否存在违法违规情况的说明
截至本上市公告书公告之日,发行人最近三年不存重大违法违规行为。
第十节 募集资金的运用
经公司第八届董事会第八次会议审议通过,并经2013年第一次临时股东大会审议通过:本次发行公司债券的募集资金拟用于偿还部分公司债务,补充公司流动资金,优化公司债务结构,改善公司资金状况。提请公司股东大会授权董事会根据公司财务状况等实际情况决定募集资金用于偿还公司债务和补充流动资金的金额、比例。
本期债券募集资金扣除发行费用后,用于偿还公司短期融资券,并拟用剩余资金补充营运资金。
第十一节 其他重要事项
本次债券发行后至本上市公告书公告之日,公司运转正常,未发生可能对本次债券的按期足额还本付息产生重大影响的重要事项。
第十二节 有关当事人
(一)发行人
名 称: 浙江尖峰集团股份有限公司
法定代表人: 蒋晓萌
住 所: 浙江省金华市婺江东路88号
电 话: 0579-82320582、82303537
传 真: 0579-82320582
联 系 人: 朱坚卫、付志坚
(二)保荐人(主承销商)/上市推荐人
名 称: 浙商证券股份有限公司
法定代表人: 吴承根
住 所: 杭州市杭大路1号
电 话: 0571-87902082、87903124
传 真: 0571-87902749
项目主办人: 华佳、周亮
项目组人员: 马岩笑、文旋、蒋盈
(三)分销商
名 称: 中信建投证券股份有限公司
法定代表人: 王常青
住 所: 北京市朝阳区安立路66号4号楼
电 话: 010-85130466
传 真: 010-85130542
联 系 人: 张慎祥、郭严、崔璐迪
(四)律师事务所
名 称: 浙江一剑律师事务所
法定代表人: 陈雄武
住 所: 浙江省金华市李渔路1018号环球商务大厦A座二楼
联 系 人: 陈雄武、左文辉
邮 编: 321017
电 话: 0579-82056936
传 真: 0579-82057299
(五)会计师事务所
名 称: 天健会计师事务所(特殊普通合伙)
法定代表人: 胡少先
住 所: 杭州市西溪路128号新湖商务大厦9楼
电 话: 0571-88216761、0571-88216764
传 真: 0571-88216870
经办会计师: 钟建国、毛晓东
(六)担保人
名 称: 天津天士力集团有限公司
法定代表人: 闫希军
住 所: 天津北辰科技园区
联 系 人: 王永胜
邮 编: 300410
电 话: 022-26736723
传 真: 022-26736720
(七)资信评级机构
名 称: 联合信用评级有限公司
法定代表人: 吴金善
住 所: 天津市南开水上公园北道38号爱俪园公寓508
电 话: 022-58356912
传 真: 022-58356989
评级人员: 刘洪涛、罗昌明
(八)本期债券受托管理人
名 称: 浙商证券股份有限公司
法定代表人: 吴承根
住 所: 杭州市杭大路1号
电 话: 0571-87902082、87903124
传 真: 0571-87902749
联 系 人: 华佳、马岩笑
(九)申请上市的证券交易所
名 称: 上海证券交易所
法定代表人: 黄红元
住 所: 上海市浦东南路528号上海证券大厦
电 话: 021-68808888
传 真: 021-68804868
(十)公司债券登记机构
名 称: 中国证券登记结算有限责任公司上海分公司
总 经 理: 高斌
住 所: 上海市浦东新区陆家嘴东路166号中国保险大厦36楼
电 话: 021-38874800
传 真: 021-58754185
第十三节 备查文件
除本上市公告书披露的资料外,备查文件如下:
一、浙江尖峰集团股份有限公司公开发行公司债券(第一期)募集说明书及其摘要;
二、中国证监会核准本次发行的文件;
三、债券受托管理协议;
四、债券持有人会议规则;
五、其他有关上市申请文件。
投资者可至发行人或保荐人(主承销商)处查阅本上市公告书全文及上述备查文件。

More information
2020
11-03
Jinhua Municipal Party Committee Secretary Chen Long: I wish your enterprise better and better
On the morning of October 16, Chen long, secretary of the Jinhua Municipal CPC Committee, and his entourage came to the construction site of Jianfeng Pharmaceutical's internationalization project to investigate and affirmed the good development status and clear future development ideas of Jianfeng Pharmaceutical. At the construction site, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, introduced the overall situation of the investment scale, factory layout, and production direction of the Jianfeng Pharmaceutical internationalization project to Chen Long and his entourage. Huang Jinlong, general manager of the pharmaceutical company, accompanied Chen Long and his entourage to visit the preparation workshop under construction. The construction site is neat, tidy and orderly, and the facilities and equipment are perfect and advanced, all have been unanimously affirmed by the leaders who came to investigate. When learning that the peak internationalization project has introduced international advanced equipment, built in accordance with European and American standards, and its products are oriented to the international market, Chen long said happily: "your goals are very clear and your thinking is very clear. I wish your enterprise better and better!" (this newspaper reporter)
2020
10-23
Liu Haiping, vice mayor of Pu'er City, said during the survey: "Peak is an enterprise with feelings"
On September 30, Liu Haiping, member of the standing Committee of the Pu'er Municipal CPC Committee and vice mayor of Pu'er City, Yunnan Province, and relevant responsible persons of Pu'er City and Simao District, visited the company for investigation and research, and communicated with the leaders of the group company on topics such as further strengthening cooperation between the two sides. "Yunnan Jianfeng has not only developed well in Pu'er these years, achieved good benefits and contributed considerable tax revenue, but also made great contributions to promoting the economic development of Pu'er and the stability of the southwest border region. It is our 'star enterprise' and 'baby enterprise '." Liu Haiping said so in the exchange. He said that Pu'er is an important window for the implementation of the "Belt and Road" concept. It has good conditions in natural resources, transportation, electricity, etc., and the peak is a "sentimental enterprise" and has a good foundation in the local area. Strengthen cooperation; various government departments will also earnestly "stand on the platform" and "do a good job as a shopkeeper" to serve enterprises. Chairman Jiang Xiaomeng and General Manager Yu Jianhong exchanged views with Liu Haiping and his party on the layout of peak industry and strengthening cooperation with Pu 'er. After that, accompanied by General Manager Yu Jianhong and Deputy General Manager Huang Jinlong, Liu Haiping and his party visited the Jinxi Factory of Jianfeng Pharmaceutical Factory. (this newspaper reporter)
2020
10-09
The first batch of Jianfeng Pharmaceuticals to enter Jinhua (Shanghai) Science and Technology Center
News from our newspaper On September 16, at the unveiling ceremony of the Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Innovation Center and Jinhua (Shanghai) Talent Building, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, took over from Chen Long, secretary of the Jinhua Municipal Party Committee. The golden key with big red flowers. Spike Pharmaceuticals became one of the first seven companies to enter the center. The Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Center and Jinhua (Shanghai) Talent Building are the first "Science and Technology and Talent Enclave" in Shanghai in the nine cities of the Yangtze River Delta G60 Science and Technology Corridor, and the first cross-regional industrial collaborative innovation center in the Science and Technology Corridor. The center is located in Shanghai Lingang Songjiang Science and Technology City, with a total area of nearly 10,000 square meters. It includes two parts: science and technology innovation and talent service. There are five major centers, including talent service center, science and technology innovation exhibition center, business incubation center, enterprise research and development center, and talent project roadshow center. It is a science and technology innovation platform that integrates the functions of project incubation, recruitment of institutions, and talent recruitment. Chen Long, secretary of the Jinhua Municipal Party Committee, said in his speech at the unveiling ceremony that in the future, all scientific and technological enterprises stationed in Jinhua (Shanghai) Science and Technology Center and Talent Building can equally enjoy Jinhua's local science and technology and talent policies, so as to further break the space limitation, enable talents from the two places to share the most favorable treatment and convenient services, help enterprises to develop in Shanghai and achieve industrialization in Jinhua. At the ceremony, leaders such as Chen Long, secretary of the Jinhua Municipal Party Committee, and Cheng Xiangmin, secretary of the Shanghai Songjiang District Party Committee, awarded seven companies, including Jianfeng Pharmaceutical, the golden key to symbolize their entry. At the Yangtze River Delta Integrated Talent Cooperation Project Symposium held after the ceremony, Jiang Xiaomeng spoke as a representative of Jinhua entrepreneurs. He believed that Shanghai, as an international metropolis, has an agglomeration effect on high-end intellectual resources and grasps the first-class element resources of scientific and technological innovation in China and even the world. The establishment of G60 Jinhua (Shanghai) science and technology innovation center and talent building in the Yangtze River Delta helps Jinhua enterprises to take off in scientific and technological innovation and information exchange, which will provide strong and continuous scientific and technological support and intellectual support for the long-term development of enterprises in the future, and attract more excellent domestic and foreign talents to serve Jinhua enterprises, It plays a key role in further improving scientific research ability, innovation ability and personnel training. During the event, Jiang Xiaomeng successively accepted on-site interviews with "People's Daily", "Liberation Daily", "Zhejiang Daily" and other media. He said that the establishment of science and technology innovation and talent bases in Shanghai has greatly enhanced Jinhua's attractiveness to enterprises. "With this base, we don't need to introduce talents to Jinhua, but directly recruit talents in Shanghai, and at the same time enjoy Jinhua's various talent recruitment policies, and change Shanghai talents to Jinhua's use. This is a kind of bold. The innovation has greatly solved the dilemma of attracting talents for enterprises." As a settled enterprise, it will also make full use of its own advantages to continuously inject resource vitality into the science and technology innovation center, and continue to contribute to the long-term development of Jinhua's economy. (this newspaper reporter)
2020
09-22
Spike Pharmaceutical Added New Products
On September 3, Spike Pharmaceutical Company received the approval of the State Drug Administration for the registration of esomeprazole sodium for injection (approval number: 2020S00572). Esomeprazole sodium for injection is mainly used to treat low-risk patients with gastroesophageal reflux disease and acute gastric or duodenal ulcer bleeding when oral therapy is not applicable. It has been listed in the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017 Edition) ", classified as Class B. According to industry statistics, 30 companies including Zhengda Tianqing and Qilu Pharmaceutical have been approved for listing in China. In 2019, domestic sales (including urban and county-level public hospitals, community and township health centers) were about 3.317 billion yuan. Jianfeng Pharmaceutical submitted an application for registration of esomeprazole sodium for injection to the State Food and Drug Administration in November 2013 and was accepted. Up to now, Jianfeng Pharmaceutical has invested nearly 15 million yuan in research and development for the project and has a corresponding production line. This time to obtain the injection of esomeprazole sodium drug registration approval, marking the peak pharmaceutical has the drug production, sales qualification, will further enrich the peak pharmaceutical product line, help to enhance the competitiveness of the peak pharmaceutical business. (Lu Yating, Liu Yang)
2020
09-11